All Categories
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI...
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and [...]
External Validation of a Post-RP Multimodal AI Prognostic Model
Prognostication after radical prostatectomy (RP) remains one of the most clinically demanding challenges in prostate cancer m [...]
Artera Expands Its Validated Multimodal AI Platform to Metastatic...
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC SAN FRANCI [...]
High-Tech Healthcare in NJ – Medical treatments advance as...
New Jersey hospitals have long been on the cutting edge of medical technology in areas ranging from cancer treatments and car [...]
Tempus and Artera Collaborate to Expand Access to New...
Tempus and Artera Collaborate to Expand Access to New Prognostic Test for Prostate Cancer
Artificial Intelligence in Oncology: Clinical Applications, Challenges, and Opportunities
Artificial intelligence (AI) is reshaping cancer research and clinical oncology by enabling large-scale analysis of complex b [...]
ASCO 2026: The biggest trends for marketers to watch
Pharma brands are expected to have a large presence in the booths at ASCO this year. Here are the biggest themes marketers sh [...]
FDA approves first AI test to guide breast cancer...
As of 2022, there were about 2.3 millionTrusted Source women around the world newly diagnosed with breast cancer, and about 6 [...]